Marmara University School of Medicine
Istanbul, Maltepe, 34854, Turkey (Türkiye)
Location status: Recruiting
Location contact
Mehmet P ATAGUNDUZ, MD
CONTACT
Şeyma ÇOLAKOĞLU-ÖZKAYA, PhD
CONTACT
NCT Number: NCT06720376
Spondyloarthritis (SpA) encompasses a group of inflammatory rheumatic diseases characterized by axial and/or peripheral arthritis, along with extra-articular manifestations such as enthesitis, dactylitis, uveitis, and skin lesions. Axial spondyloarthritis (axSpA), the hallmark of which is chronic sacroiliitis, can progress to vertebral fusion ("bamboo spine") in advanced cases. The prevalence of axSpA varies globally, ranging from 0.1% to 1.4%, with a higher incidence in men and a typical onset in the second or third decades of life. Diagnostic approaches include imaging techniques such as sacroiliac MRI and radiographs, alongside clinical criteria like inflammatory back pain, NSAID responsiveness, peripheral arthritis, and HLA-B27 positivity. Disease management primarily involves NSAIDs, with biologics used for refractory cases, and disease activity is monitored using indices such as BASDAI and ASDAS.
Acute anterior uveitis (AAU) is the most common extra-articular manifestation of SpA, particularly associated with HLA-B27 positivity. It often presents unilaterally with redness, pain, and photophobia but can lead to severe complications if inadequately treated. Around 50% of patients with HLA-B27-positive AAU have underlying SpA, and the prevalence of uveitis increases with longer disease duration. While the link between SpA and AAU is well-established, further research is needed to determine optimal systemic treatment and follow-up protocols. This study aims to assess the prevalence and clinical characteristics of SpA in patients presenting with AAU at ophthalmology clinics.
Interested in participating?
Request Info18 year–75 year
All sexes
Observational
Istanbul, Maltepe, 34854, Turkey (Türkiye)
Location status: Recruiting
Mehmet P ATAGUNDUZ, MD
CONTACT
Şeyma ÇOLAKOĞLU-ÖZKAYA, PhD
CONTACT
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: Cross-sectional anaylsis of the first two hundered patients for the prevalance of Spondyloarthritis is anticipated to be analyzed at the end of the second year after the inclusion of the first patient with acute anterior uveits.
Presence of undiagnosed or known Spondyloarthritis will be assessed in a cross-sectional manner at time of acute anterior uveitis.
Time frame: Cross-sectional anaylsis of the first two hundered patients for the prevalance of Spondyloarthritis is anticipated to be analyzed at the end of the fifth year after the inclusion of the last patient with acute anterior uveits.
Development of an full-blown Spondyloarthritis will be assessed long-term in a prospective manner.
Time frame: Cross-sectional anaylsis of the first two hundered patients for the prevalance of HLA-B27 is anticipated to be analyzed at the end of the second year after the inclusion of the first patient with acute anterior uveits.
HLA-B27 status will be assessed in patints with idiopathic acute- and spondyloarthritis associated anterior uveitis will be assessed.
Contact information is provided by the study sponsor or research team.
Mehmet P ATAGUNDUZ, MD
CONTACT
Şeyma ÇOLAKOĞLU-ÖZKAYA, PhD
CONTACT
Marmara University
Other
Assessment of Spondyloarthritis in an Acute Anterior Uveitis Inception Cohort: a Cross Sectional and Prospective Comparative Study of HLA-B27-positive and -negative Cases
Acronym: OPTICUS
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07077304
ANCA Associated Vasculitis, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Paris, France
View Trial DetailsNCT06320899
Arthritis, Bone Diseases
Aarberg, Switzerland
View Trial DetailsNCT05592574
Arthritis, Bone Diseases
Nice, France
View Trial DetailsNCT07721844
Arthritis, Bone Diseases
Asyut, Asyut Governorate, Egypt
View Trial Details